Phase II/III (Integrated)

402 trials 182 recruiting

Filter these 402 trials by condition, country, sponsor and more.

Open in Search →

Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 2022-11-10
An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in … Recruiting

2023-505766-28-00 Hereditary angioedema 2022-10-10
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Subcutaneously in Children With Generalized Myasthenia Gravis (AD… Recruiting

2023-507379-23-00 Generalized Myasthenia Gravis 2022-08-18
A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral oza… Recruiting

2023-509248-86-00 Moderately to Severely Active Ulcerative Colitis 2022-03-11
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 2021-03-17
CIRAANO: Multimodal exploration of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strat… Recruiting

2025-523264-21-00 Semantic Variant Primary Progressive Aphasia 2026-06-04
A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated all… Recruiting

2025-524580-21-00 Grass pollen induced allergic rhinitis or rhinoconjunct 2026-06-01
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which has Spread and Caused Significant Body Weight Lo… Recruiting

2025-522093-36-00 Cancer cachexia 2026-05-20
A novel fibroblast imaging biomarker and ultrahigh resolution PET to improve the diagnosis and follow-up of giant cell arteritis Recruiting

2025-523880-39-02 Giant Cell Arteritis 2026-05-04
Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positiv… Recruiting

2024-516582-36-00 Early stage HER2-positive breast cancer 2026-05-01
Insulin nasal spray to prevent delirium after cardiac surgery Recruiting

2025-524680-21-00 Delirium 2026-04-29
A clinical study is aimed at comparing the effectiveness of two types of cell therapy in treating anal fistulas associated with Crohn's dise… Recruiting

2024-518898-34-00 Anal or recto-cutaneous or recto-vaginal Crohn-related 2026-04-21
Neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab versus upfront surgery for patients with primary resec… Recruiting

2024-516898-72-00 Perihilar cholangiocarcinoma, distal cholangiocarcinoma 2026-04-17
Immunosuppression regimen reduction in kidney transplantation recipients admitted to the intensive care unit in the setting of septic shock … Recruiting

2024-518493-14-00 kidney transplant 2026-04-10
Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Previously Untreated Advanced or Me… Recruiting

2025-523263-37-00 Previously Untreated Advanced or Metastatic Gastric, Ga 2026-04-08
Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met… Recruiting

2025-523224-45-00 Untreated, Unresectable or Metastatic Colorectal Cancer 2026-03-30
Visugromab in Cachexia International Trial Recruiting

2025-523533-25-00 Cancer-associated Cachexia 2026-03-26
Phase 2a Study of Tafasitamab in Adults With Primary Autoimmune Blood Cell Disorders Recruiting

2025-521286-27-00 Immune-mediated thrombocytopenia, Autoimmune thrombocyt 2026-03-26
Not Applicable Recruiting

2024-511198-31-00 Lupus Nephritis 2026-03-24
A clinical study of islatravir and ulonivirine for people with HIV-1 who have not been treated before (MK-8591B-062) Recruiting

2025-522519-40-00 HIV 2026-03-16
Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Recruiting

2025-522015-42-00 Chronic Hepatitis D Infection 2026-02-26
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum… Recruiting

2025-520897-21-00 Multiple Myeloma 2026-02-25
Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Recruiting

2024-510575-38-00 Relapsed and refractory mature B-cell non-Hodgkin Lymph 2026-02-24
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad… Recruiting

2025-521124-29-00 Non-Small Cell Lung Cancer 2026-02-13